What is the antimicrobial spectrum comparison of meropenem, polymyxin, and tigecycline versus Zavicefta (ceftazidime‑avibactam), aztreonam, and tigecycline?

Antimicrobial Spectrum Comparison

For carbapenem-resistant Enterobacterales (CRE), particularly metallo-β-lactamase producers, the combination of Zavicefta (ceftazidime-avibactam) plus aztreonam demonstrates superior mortality reduction compared to older regimens of meropenem, polymyxin, and tigecycline.

Spectrum Against Carbapenem-Resistant Enterobacterales (CRE)

Zavicefta + Aztreonam + Tigecycline Regimen

Ceftazidime-avibactam (Zavicefta) exhibits excellent activity against KPC-producing and OXA-48-producing CRE (nearly 100% susceptible) 1. However, it has minimal activity against metallo-β-lactamase (MBL) producers (only 3.8% susceptible) 1.

The critical advantage emerges when combining ceftazidime-avibactam with aztreonam for MBL-producing CRE:

• 30-day mortality: 19.2% versus 44% with other regimens (HR 0.37,95% CI 0.13-0.74) 1
• Clinical treatment failure reduced by 70% (HR 0.30,95% CI 0.14-0.65) 1
• Curative rate of 77.5% for NDM-positive CRE 1

Aztreonam is not hydrolyzed by metallo-β-lactamases, making it uniquely effective when combined with ceftazidime-avibactam, which protects aztreonam from other β-lactamases 1. Recent surveillance shows aztreonam-avibactam inhibits 95.8-100% of CRE, including those resistant to ceftazidime-avibactam alone 2, 3.

Tigecycline in this regimen provides additional coverage but has significant limitations:

• Should NOT be used for bloodstream infections or pneumonia 4
• May use high-dose tigecycline for pneumonia if necessary 4
• Efficacy depends on MIC ≤2 mg/L 1

Meropenem + Polymyxin + Tigecycline Regimen

Meropenem has broad gram-negative coverage including:

• Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis 5
• Pseudomonas aeruginosa 5
• Haemophilus influenzae, Neisseria meningitidis 5
• NO activity against MRSA or MRSE 5

Critical limitation: Meropenem is ineffective against CRE by definition, as these organisms are carbapenem-resistant. Guidelines explicitly recommend avoiding carbapenem-based therapy for CRE unless MIC ≤8 mg/L with high-dose extended infusion 4.

Polymyxin (colistin) provides activity against CRE but:

• Significant nephrotoxicity risk (225 fewer nephrotoxicity events per 1000 patients with tigecycline versus polymyxin) 1
• Should be used judiciously in renal insufficiency 1
• When used for CRE, combination therapy is suggested over monotherapy 4

Tigecycline in this regimen:

• Comparable mortality to polymyxin-based therapy for CRAB (both equally preferable) 1
• Should be used cautiously in liver insufficiency 1
• Strong recommendation AGAINST use for 3rd-generation cephalosporin-resistant Enterobacterales 4

Spectrum Against Pseudomonas aeruginosa

Ceftazidime-avibactam shows superior activity:

• 95.7% susceptible in immunocompromised patients 6
• 77.2% of P. aeruginosa inhibited at ≤8 mg/L for aztreonam-avibactam 2

Meropenem demonstrates:

• Good baseline activity against P. aeruginosa 5
• 82.5% susceptible in recent surveillance 6
• Synergistic with aminoglycosides 5

Key Clinical Decision Points

For severe CRE infections:

1. Identify carbapenemase type before treatment when possible 1
2. If KPC or OXA-48: Use ceftazidime-avibactam monotherapy 4, 1
3. If MBL-producing (NDM, VIM, IMP): Use ceftazidime-avibactam PLUS aztreonam 1
4. Avoid tigecycline for bloodstream infections 4

For non-severe CRE infections:

• Consider older agents (polymyxin, aminoglycosides) based on susceptibility and infection site 4
• Aminoglycosides preferred over tigecycline for complicated UTI 4

Common pitfalls:

• Using meropenem for documented CRE (ineffective by definition)
• Using tigecycline for bacteremia (associated with higher mortality)
• Using ceftazidime-avibactam alone for MBL producers (only 3.8% susceptible)
• Ignoring nephrotoxicity risk with polymyxin in renal insufficiency
• Not checking tigecycline MIC (efficacy requires MIC ≤2 mg/L) 1

The alarming trend: MBL producers now represent 23.5% of carbapenemases in US hospitals (2023-2024), with NDM being most common 3, 6. This makes the ceftazidime-avibactam plus aztreonam combination increasingly critical, as it remains 98.1-100% effective against these isolates 2, 3.